Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi Long

Showing results (41-50 of 1,617) with videos related to

Pageof 162
Sort By:
Trends in Pharmacological Sciences|October 9, 2016
EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?E-E -Ke, Yi-Long Wu
Biosensors & Bioelectronics|March 23, 2013
An isothermal and sensitive nucleic acids assay by target sequence recycled rolling circle amplificationYi Long, Xiaoming Zhou, Da Xing
JAMA Internal Medicine|July 17, 2023
Ventricular Arrest With a Duration of 23.8 SecondsZhongzheng Zhou, Yi Long, Yong Li
Translational Lung Cancer Research|December 21, 2019
Biomarker for personalized immunotherapySi-Yang Liu, Yi-Long Wu
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of ChinaLan-Ying Gou, Yi-Long Wu
Experimental Hematology & Oncology|January 14, 2014
Novel agents and strategies for overcoming EGFR TKIs resistanceFei-Yu Niu, Yi-Long Wu
ESMO Open|December 10, 2016
CSCO joins ESMO Open-Cancer HorizonsChristoph C Zielinski, Yi-Long Wu
Journal of Thoracic Disease|September 28, 2019
Personalized adjuvant treatment: go through the past to the futureSi-Yang Liu, Yi-Long Wu
Journal of Thoracic Disease|February 13, 2019
Adjuvant TKIs: still an optimal choiceSi-Yang Liu, Yi-Long Wu
Journal of Hematology & Oncology|July 7, 2017
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in ChinaSi-Yang Liu, Yi-Long Wu
Pageof 162

Showing results (41-50 of 1,617) with videos related to

Sort By:
Pageof 162
Trends in Pharmacological Sciences|October 9, 2016
EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?E-E -Ke, Yi-Long Wu
Biosensors & Bioelectronics|March 23, 2013
An isothermal and sensitive nucleic acids assay by target sequence recycled rolling circle amplificationYi Long, Xiaoming Zhou, Da Xing
JAMA Internal Medicine|July 17, 2023
Ventricular Arrest With a Duration of 23.8 SecondsZhongzheng Zhou, Yi Long, Yong Li
Translational Lung Cancer Research|December 21, 2019
Biomarker for personalized immunotherapySi-Yang Liu, Yi-Long Wu
Lung Cancer (Auckland, N.Z.)|February 18, 2017
Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of ChinaLan-Ying Gou, Yi-Long Wu
Experimental Hematology & Oncology|January 14, 2014
Novel agents and strategies for overcoming EGFR TKIs resistanceFei-Yu Niu, Yi-Long Wu
ESMO Open|December 10, 2016
CSCO joins ESMO Open-Cancer HorizonsChristoph C Zielinski, Yi-Long Wu
Journal of Thoracic Disease|September 28, 2019
Personalized adjuvant treatment: go through the past to the futureSi-Yang Liu, Yi-Long Wu
Journal of Thoracic Disease|February 13, 2019
Adjuvant TKIs: still an optimal choiceSi-Yang Liu, Yi-Long Wu
Journal of Hematology & Oncology|July 7, 2017
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in ChinaSi-Yang Liu, Yi-Long Wu
Pageof 162